<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003797</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066940</org_study_id>
    <secondary_id>BRUOG-PA-77</secondary_id>
    <secondary_id>NCI-T98-0067</secondary_id>
    <nct_id>NCT00003797</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas</brief_title>
  <official_title>Herceptin (NSC #688097) and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/NEU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells&#xD;
      and either kill them or deliver tumor-killing substances to them without harming normal&#xD;
      cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of gemcitabine and trastuzumab in treating&#xD;
      patients who have metastatic cancer of the pancreas that overexpresses HER2/neu.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate and survival of patients with metastatic pancreatic cancer&#xD;
           and overexpression of HER2/neu treated with gemcitabine and trastuzumab.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive gemcitabine IV over 30 minutes once weekly during weeks 1-7. Patients&#xD;
      receive trastuzumab IV over 90 minutes once during week 1 and trastuzumab IV over 30-90&#xD;
      minutes once weekly during weeks 2-8.&#xD;
&#xD;
      Patients with stable or responding disease receive gemcitabine IV over 30 minutes once weekly&#xD;
      during weeks 1-3 and trastuzumab IV over 30 minutes once weekly during weeks 1-4. Courses&#xD;
      repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 41 patients will be accrued for this study over 18-24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic pancreatic cancer with overexpression of HER2/neu&#xD;
&#xD;
          -  Patients in whom there is inadequate tissue to evaluate for HER2/neu overexpression&#xD;
             but who have elevated serum HER2/neu antigen levels are eligible&#xD;
&#xD;
          -  Radiographically measurable disease&#xD;
&#xD;
               -  May have metastatic disease in which primary lesion is measurable but metastatic&#xD;
                  lesions are not measurable&#xD;
&#xD;
               -  Ascites is not measurable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL&#xD;
&#xD;
               -  Greater than 3 times normal if increase in bilirubin is due to biliary&#xD;
                  obstruction from tumor as long as biliary system is stented or bypassed and&#xD;
                  bilirubin, SGOT, or SGPT is stable or decreasing&#xD;
&#xD;
          -  SGOT no greater than 3 times normal&#xD;
&#xD;
               -  No greater than 5 times normal if liver metastases present OR&#xD;
&#xD;
               -  Greater than 5 times normal if increase in SGOT or SGPT is due to biliary&#xD;
                  obstruction from tumor as long as biliary system is stented or bypassed and&#xD;
                  biliary SGOT or SGPT is stable or decreasing&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No prior congestive heart failure&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  LVEF at least 45% by MUGA or echocardiogram&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior trastuzumab&#xD;
&#xD;
          -  No concurrent growth factors&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior anthracyclines&#xD;
&#xD;
          -  No prior gemcitabine except prior low dose (no greater than 300 mg/m2/week)&#xD;
             gemcitabine with radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior adjuvant therapy&#xD;
&#xD;
          -  More than 2 weeks since other prior chemotherapy&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Safran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush-Presbyterian-St. Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135-2997</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Rhode Island</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Williams Medical Center/BUSM</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908-4735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University Oncology Group</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

